Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study
- PMID: 15998902
- DOI: 10.1200/JCO.2005.23.622
Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study
Abstract
Background: Temsirolimus (CCI-779) is a small-molecule inhibitor of the mammalian target of rapamycin (mTOR) and represents a rational therapeutic target against glioblastoma multiforme (GBM).
Methods: Recurrent GBM patients with < or = 1 chemotherapy regimen for progressive disease were eligible. Temsirolimus was administered in a 250-mg intravenous dose weekly.
Results: Sixty-five patients were treated. The incidence of grade 3 or higher nonhematologic toxicity was 51%, and consisted mostly of hypercholesterolemia (11%), hypertriglyceridemia (8%), and hyperglycemia (8%). Grade 3 hematologic toxicity was observed in 11% of patients. Temsirolimus peak concentration (Cmax), and sirolimus Cmax and area under the concentration-time curve were decreased in patients receiving p450 enzyme-inducing anticonvulsants (EIACs) by 73%, 47%, and 50%, respectively, but were still within the therapeutic range of preclinical models. Twenty patients (36%) had evidence of improvement in neuroimaging, consisting of decrease in T2 signal abnormality +/- decrease in T1 gadolinium enhancement, on stable or reduced steroid doses. Progression-free survival at 6 months was 7.8% and median overall survival was 4.4 months. Median time to progression (TTP) for all patients was 2.3 months and was significantly longer for responders (5.4 months) versus nonresponders (1.9 months). Development of grade 2 or higher hyperlipidemia in the first two treatment cycles was associated with a higher percentage of radiographic response (71% v 31%; P = .04). Significant correlation was observed between radiographic improvement and high levels of phosphorylated p70s6 kinase in baseline tumor samples (P = .04).
Conclusion: Temsirolimus is well tolerated in recurrent GBM patients. Despite the effect of EIACs on temsirolimus metabolism, therapeutic levels were achieved. Radiographic improvement was observed in 36% of temsirolimus-treated patients, and was associated with significantly longer TTP. High levels of phosphorylated p70s6 kinase in baseline tumor samples appear to predict a patient population more likely to derive benefit from treatment. These findings should be validated in other studies of mTOR inhibitors.
Similar articles
-
Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.Anticancer Res. 2013 Apr;33(4):1657-60. Anticancer Res. 2013. PMID: 23564811 Clinical Trial.
-
Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199).Gynecol Oncol. 2013 Aug;130(2):269-74. doi: 10.1016/j.ygyno.2013.05.008. Epub 2013 May 11. Gynecol Oncol. 2013. PMID: 23672928 Clinical Trial.
-
Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma.PLoS Med. 2008 Jan 22;5(1):e8. doi: 10.1371/journal.pmed.0050008. PLoS Med. 2008. PMID: 18215105 Free PMC article. Clinical Trial.
-
Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma.Clin J Oncol Nurs. 2008 Aug;12(4):639-46. doi: 10.1188/08.CJON.639-646. Clin J Oncol Nurs. 2008. PMID: 18676330 Review.
-
[Update on clinical activity of CCI779 (temsirolimus), mTOR inhibitor].Bull Cancer. 2006 Nov;93(11):1139-43. Bull Cancer. 2006. PMID: 17145584 Review. French.
Cited by
-
Novel Clinical Trials and Approaches in the Management of Glioblastoma.Curr Oncol Rep. 2024 May;26(5):439-465. doi: 10.1007/s11912-024-01519-4. Epub 2024 Mar 28. Curr Oncol Rep. 2024. PMID: 38546941 Review.
-
Discrete Mechanistic Target of Rapamycin Signaling Pathways, Stem Cells, and Therapeutic Targets.Cells. 2024 Feb 27;13(5):409. doi: 10.3390/cells13050409. Cells. 2024. PMID: 38474373 Free PMC article. Review.
-
Glioblastoma Therapy: Past, Present and Future.Int J Mol Sci. 2024 Feb 21;25(5):2529. doi: 10.3390/ijms25052529. Int J Mol Sci. 2024. PMID: 38473776 Free PMC article. Review.
-
A Systematic Review of the Metabolism of High-Grade Gliomas: Current Targeted Therapies and Future Perspectives.Int J Mol Sci. 2024 Jan 5;25(2):724. doi: 10.3390/ijms25020724. Int J Mol Sci. 2024. PMID: 38255798 Free PMC article. Review.
-
Nanomedicine for cancer targeted therapy with autophagy regulation.Front Immunol. 2024 Jan 4;14:1238827. doi: 10.3389/fimmu.2023.1238827. eCollection 2023. Front Immunol. 2024. PMID: 38239356 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous